Experimental combo therapy targets multiple cancers in new trial
NCT ID NCT06814496
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusions along with radiation, either at the same time or one after the other. The main goal is to check for serious side effects, and a smaller part of the study will look at whether the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tarlatamab (a drug that helps immune cells attack cancer) and radiation therapy
What this could lead to
If successful, this could point toward a new treatment option for several hard-to-treat cancers that have a specific protein (DLL3) on their surface.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to everyone. Combining tarlatamab with radiation could cause serious side effects like inflammation or nerve problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arizona Cancer Center at UMC North/University Medical Center
RECRUITINGTucson, Arizona, 85719, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Washington Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••